This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
AMRX Valuation: What 1.69x Sales Means for Investors
by Kanishka Das
Amneal trades at 1.69x sales, below sector benchmarks, as investors weigh raised 2026 profit guidance against Specialty pressure and launch execution.
RDYNegative Net Change TEVANegative Net Change AMRXNegative Net Change
biotechs medical
AMRX Growth Drivers: Generics, Biosimilars, and Crexont
by Kanishka Das
Amneal leans on generics stability, biosimilar launches, and Crexont growth as 2026 guidance points to higher EBITDA and EPS despite Specialty headwinds.
TEVANegative Net Change AMRXNegative Net Change SDZNYNegative Net Change
biotechs medical
Amgen to Report Q1 Earnings: Can It Keep the Beat Streak Alive?
by Zacks Equity Research
Amgen heads into Q1 earnings with growth from key drugs offset by pricing pressure, patent losses, and biosimilar competition.
REGNNegative Net Change AMGNNegative Net Change GILDPositive Net Change
biotechs
INCY Q1 Earnings and Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte tops Q1 estimates with $1.27 billion in revenues and strong earnings, fueled by Jakafi growth and rising Opzelura demand.
NVSNegative Net Change LLYNegative Net Change INCYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?
by Ahan Chakraborty
Novo Nordisk bets on oral Ozempic launch and pediatric label expansions to counter slowing demand, pricing pressure and rising competition in the GLP-1 market.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Moderna Gears Up to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
MRNA heads into Q1 earnings with expected sales growth, new vaccine momentum and focus on pipeline updates amid tough RSV competition.
MRKPositive Net Change MRNANegative Net Change AGENNegative Net Change INONegative Net Change
biotechs earnings medical pharmaceuticals
Is IBRX Priced for Perfection at Nearly 28x Forward Sales?
by Sundeep Ganoria
ImmunityBio trades near 28x forward sales after a massive run, but can ImmunityBio sustain execution to justify a premium that leaves little room for missteps?
REGNNegative Net Change BMYNegative Net Change IBRXNegative Net Change
biotechs immuno-therapy medical
IBRX Global Rollout: EU, MENA, and Asia Shape 2026-27 Catalysts
by Sundeep Ganoria
ImmunityBio's global push spans EU, MENA, and Asia, with early Saudi sales and key 2026 data readouts set to test demand and drive next growth phase.
BMYNegative Net Change MRKPositive Net Change IBRXNegative Net Change
biotechs immuno-therapy medical
IBRX: What Anktiva's Bladder Data Says About 2026 Sales
by Sundeep Ganoria
ImmunityBio heads into 2026 riding Anktiva growth, but upcoming bladder trial data and broader use in earlier care will be key to sustaining momentum.
MRKPositive Net Change URGNNegative Net Change IBRXNegative Net Change
biotechs immuno-therapy medical
NVS SMA Drug Gets CHMP Backing, Malaria Drug Wins WHO Prequalification
by Zacks Equity Research
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
NVSNegative Net Change ANIPNegative Net Change INDVNo Net Change
biotechs